GlassScriptPhysician profile
Daniel Agraz
NPI 1578092839
$3,568.79
in general payments reported to CMS, 2019-2025
13 companies · $531 in 2025
The $531 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,247 · 2020: $351 · 2021: $290 · 2023: $35.47 · 2024: $114 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600 · Entertainment: $63.06 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.70 |
| Entertainment | $63.06 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,591.16 | 2019 | |
| Alcon Vision LLC | $1,058.91 | 2019-2021 | |
| Abbvie INC. | $384.94 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $138.77 | 2019-2021 | |
| Dompe US, INC. | $88.25 | 2024-2025 | Oxervate |
| Optos, INC. | $63.06 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $58.90 | 2023-2025 | |
| Glaukos Corporation | $54.08 | 2025 | Idosetr, Istent Infinite |
| Sight Sciences, INC. | $41.66 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $39.82 | 2021 | |
| Aerie Pharmaceuticals, INC. | $17.87 | 2021 | |
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
| Glaxosmithkline, LLC. | $13.53 | 2025 | Blenrep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Agraz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.